New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:59 EDTVCYTVeracyte shares well positioned in 2014, says Leerink
Leerink believes Veracyte shares are well positioned in 2014 with potential catalysts from additional positive coverage decisions and the launch of the Afirma malignant test. The firm raised its price target for shares to $21 from $17 and maintains an Outperform rating on the name.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
16:13 EDTVCYTVeracyte performed 4,071 Afirma GEC tests in Q4
Subscribe for More Information
16:13 EDTVCYTVeracyte sees FY15 revenue $48M-$53M, consensus $59.13M
Subscribe for More Information
16:12 EDTVCYTVeracyte sees achieving 2015 Afirma GEC test volume of 19K-21K
Subscribe for More Information
16:11 EDTVCYTVeracyte reports Q4 EPS (36c), consensus (33c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use